Novartis AG (SWX:NOVNEE)
Switzerland flag Switzerland · Delayed Price · Currency is CHF
120.84
-0.76 (-0.62%)
Last updated: Mar 12, 2026, 4:31 PM CET

Novartis AG Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
13,96711,9398,5726,04922,905
Other Adjustments
8,237-2,7397,5517,786-9,467
Changes in Other Operating Activities
-1,577-706-1314011,633
Operating Cash Flow
19,1448,49414,45814,23615,071
Operating Cash Flow Growth
125.38%-41.25%1.56%-5.54%10.41%
Capital Expenditures
----916-1,066
Sale of Property, Plant & Equipment
---158211
Purchases of Intangible Assets
----1,323-1,490
Proceeds from Sale of Intangible Assets
---170686
Purchases of Investments
----34,810-16,591
Proceeds from Sale of Investments
---39,4902,738
Payments for Business Acquisitions
-2,916-4,018-3,561-840-205
Other Investing Activities
-112100-1,131-46019,925
Investing Cash Flow
-4,877-3,9185,5961,4684,208
Short-Term Debt Issued
---252-3,547
Short-Term Debt Repaid
--289---
Net Short-Term Debt Issued (Repaid)
--289-252-3,547
Long-Term Debt Repaid
-3,392-2,160-2,223-2,575-2,162
Net Long-Term Debt Issued (Repaid)
-3,392-2,160-2,223-2,575-2,162
Issuance of Common Stock
273015310053
Repurchase of Common Stock
-9,212-8,331-8,719-10,652-3,057
Net Common Stock Issued (Repurchased)
-9,185-8,301-8,566-10,552-3,004
Common Dividends Paid
----7,506-7,368
Other Financing Activities
-575-4693,220-181-183
Financing Cash Flow
-14,867-11,219-14,278-20,562-16,264
Effect of Exchange Rate Changes on Cash and Cash Equivalents
576-100-32-266
Net Cash Flow
-24-1,9345,876-4,8902,749
Free Cash Flow
19,1448,49414,45813,32014,005
Free Cash Flow Growth
125.38%-41.25%8.54%-4.89%13.17%
FCF Margin
33.78%16.42%30.99%30.65%31.85%
Free Cash Flow Per Share
9.794.176.916.066.20
Levered Free Cash Flow
9,0158,78612,4964,11718,879
Unlevered Free Cash Flow
13,49412,0249,0486,1829,957
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.